CJC-1295 Side Effects: What Studies and Users Report
What FDA labels and clinical studies report for CJC-1295, how strong that evidence is, and what is still unknown.
Side effects reported in studies
Side effects reported in published studies, strongest design first. Frequencies are quoted as the source gives them; animal results are labelled.
| Side effect | How common | Study type | Source |
|---|---|---|---|
| Serious adverse reactions“No serious adverse reactions were reported.” | Frequency not stated | Human RCT | The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 |
| Tolerability“was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg.” | Frequency not stated | Human RCT | The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 |
What is not known
- How common each effect is at the doses people use outside of studies.
- Effects that take longer to appear than the length of the published studies.
- How CJC-1295 interacts with other medicines and supplements.
- Whether research-grade products, which are not checked by the FDA, behave like the material used in studies.
When to get medical help
This is not a complete list. A doctor or pharmacist can help you judge whether a symptom is related.
Common questions
What are the side effects of CJC-1295?
Studies we summarise reported serious adverse reactions, tolerability. The table on this page gives how often each happened and links each source.
Is CJC-1295 safe?
CJC-1295 has an FDA-approved label that lists its known risks. That label covers the approved product used as prescribed, not compounded or research-chemical versions.
Is CJC-1295 banned in sport?
Yes. Prohibited by WADA (S2.2.4). Tested athletes should not use it.
More on CJC-1295
Sources
- 1Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
Found an error? Report a correction.